Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Proposal of a clinical typing system and generation of a prognostic model in patients with nasopharyngeal carcinoma from Southern China.

Sun P, Chen C, Chen XL, Cheng YK, Zeng L, Zeng ZJ, Liu LZ, Su Y, Gu MF.

J BUON. 2014 Apr-Jun;19(2):474-83.

PMID:
24965409
2.
3.

Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.

Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.

Cancer. 2004 Mar 15;100(6):1162-70.

4.

Serologic biomarkers of Epstein-Barr virus correlate with TNM classification according to the seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma.

Sun P, Chen C, Cheng YK, Zeng ZJ, Chen XL, Liu LZ, Gu MF.

Eur Arch Otorhinolaryngol. 2014 Sep;271(9):2545-54. doi: 10.1007/s00405-013-2805-5. Epub 2013 Nov 9.

PMID:
24213277
5.

[Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].

Hou X, Zhang L, Zhao C, Li S, Lu LX, Han F, Shao JY, Huang PY.

Ai Zheng. 2006 Jul;25(7):785-92. Chinese.

PMID:
16831265
6.

Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.

Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ.

J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9.

7.

Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.

Shen T, Tang LQ, Luo DH, Chen QY, Li PJ, Mai DM, Guo SS, Liu LT, Qian CN, Guo X, Zeng MS, Mo HY, Mai HQ.

PLoS One. 2015 Apr 8;10(4):e0122756. doi: 10.1371/journal.pone.0122756. eCollection 2015.

8.
9.

Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.

Shao JY, Huang XM, Yu XJ, Huang LX, Wu QL, Xia JC, Wang HY, Feng QS, Ren ZF, Ernberg I, Hu LF, Zeng YX.

Anticancer Res. 2001 Jul-Aug;21(4B):3021-9.

PMID:
11712805
10.

Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.

Ji MF, Huang QH, Yu X, Liu Z, Li X, Zhang LF, Wang P, Xie SH, Rao HL, Fang F, Guo X, Liu Q, Hong MH, Ye W, Zeng YX, Cao SM.

Cancer. 2014 May 1;120(9):1353-60. doi: 10.1002/cncr.28564. Epub 2014 Jan 29.

11.

[Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].

Cao SM, Min HQ, Gao JS, Hong MH, Xiao XB, Zhang CQ, Liu XD, Zhang AL, Guo X.

Ai Zheng. 2003 Mar;22(3):302-6. Chinese.

PMID:
12654192
12.

[Prognostic significance of serum anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma].

Cai YL, Li J, Lu AY, Zhong WM, Zheng YM, Gao JQ, Zeng H, Chen WS, Liang W, Tang MZ.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013 Apr;27(2):119-22. Chinese.

PMID:
24044217
13.
14.

Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.

Lin JC, Wang WY, Liang WM, Chou HY, Jan JS, Jiang RS, Wang JY, Twu CW, Liang KL, Chao J, Shen WC.

Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1342-8. Epub 2007 Apr 20.

PMID:
17449194
15.

Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.

Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, Chan KC, Chan LY, Kwan WH, Lo YM, Chan AT.

J Clin Oncol. 2006 Dec 1;24(34):5414-8.

16.

Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival.

Lin JC, Chen KY, Wang WY, Jan JS, Liang WM, Tsai CS, Wei YH.

J Clin Oncol. 2001 May 15;19(10):2607-15.

PMID:
11352952
18.

Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.

Twu CW, Wang WY, Liang WM, Jan JS, Jiang RS, Chao J, Jin YT, Lin JC.

Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):130-7. Epub 2006 Sep 18.

PMID:
16979842
19.

Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up.

Cao SM, Liu Z, Jia WH, Huang QH, Liu Q, Guo X, Huang TB, Ye W, Hong MH.

PLoS One. 2011 Apr 22;6(4):e19100. doi: 10.1371/journal.pone.0019100.

20.

High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study.

Tang LQ, Li CF, Chen QY, Zhang L, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Chen WH, Liu H, Guo SS, Liu LT, Li J, Zhang JP, Guo L, Zhao C, Cao KJ, Qian CN, Zeng YX, Guo X, Mai HQ, Zeng MS.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):325-36. doi: 10.1016/j.ijrobp.2014.10.005. Epub 2014 Dec 5.

PMID:
25482300
Items per page

Supplemental Content

Write to the Help Desk